Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects

Aim Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Cauca...

Full description

Saved in:
Bibliographic Details
Published inInvestigational new drugs Vol. 42; no. 1; pp. 80 - 88
Main Authors Kim, Hyun Chul, Yang, Eunsol, Lee, Soyoung, Oh, Jaeseong, Lee, Myongjae, Lee, ChaeEun, Ha, Kyoung Soo, Lee, Won Sik, Jang, In-Jin, Yu, Kyung-Sang
Format Journal Article
LanguageEnglish
Published New York Springer US 01.02.2024
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. Methods In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Results Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (C max ) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUC last ) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in C max ( P -value = 0.45) or AUC last ( P -value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. Conclusion The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased C max in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
AbstractList Aim Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. Methods In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Results Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (C max ) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUC last ) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in C max ( P -value = 0.45) or AUC last ( P -value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. Conclusion The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased C max in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (C ) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUC ) of venadaparib for the fed to fasted state were 0.82 (0.7457-0.9094) and 1.02 (0.9088-1.1339) in Koreans, and 0.77 (0.6871-0.8609) and 0.96 (0.9017-1.0186) in Caucasians, respectively. No statistically significant differences were observed in C (P-value = 0.45) or AUC (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased C in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.AIMVenadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.METHODSIn this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457-0.9094) and 1.02 (0.9088-1.1339) in Koreans, and 0.77 (0.6871-0.8609) and 0.96 (0.9017-1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.RESULTSTwelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457-0.9094) and 1.02 (0.9088-1.1339) in Koreans, and 0.77 (0.6871-0.8609) and 0.96 (0.9017-1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.CONCLUSIONThe overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
AimVenadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.MethodsIn this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.ResultsTwelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.ConclusionThe overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
Author Ha, Kyoung Soo
Jang, In-Jin
Lee, Won Sik
Yu, Kyung-Sang
Yang, Eunsol
Kim, Hyun Chul
Lee, Soyoung
Lee, Myongjae
Oh, Jaeseong
Lee, ChaeEun
Author_xml – sequence: 1
  givenname: Hyun Chul
  orcidid: 0000-0002-8819-4780
  surname: Kim
  fullname: Kim, Hyun Chul
  organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Integrated Major in Innovative Medical Science, Seoul National University Graduate School
– sequence: 2
  givenname: Eunsol
  orcidid: 0000-0003-2581-349X
  surname: Yang
  fullname: Yang, Eunsol
  organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
– sequence: 3
  givenname: Soyoung
  orcidid: 0000-0001-5799-4489
  surname: Lee
  fullname: Lee, Soyoung
  organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Kidney Research Institute, Seoul National University Medical Research Center
– sequence: 4
  givenname: Jaeseong
  orcidid: 0000-0001-6275-8587
  surname: Oh
  fullname: Oh, Jaeseong
  organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Department of Pharmacology, Jeju National University College of Medicine
– sequence: 5
  givenname: Myongjae
  orcidid: 0000-0002-0306-6908
  surname: Lee
  fullname: Lee, Myongjae
  organization: Idience Co., Ltd
– sequence: 6
  givenname: ChaeEun
  orcidid: 0009-0005-4285-4439
  surname: Lee
  fullname: Lee, ChaeEun
  organization: Idience Co., Ltd
– sequence: 7
  givenname: Kyoung Soo
  orcidid: 0000-0002-1216-7516
  surname: Ha
  fullname: Ha, Kyoung Soo
  organization: Idience Inc
– sequence: 8
  givenname: Won Sik
  orcidid: 0000-0001-9502-2429
  surname: Lee
  fullname: Lee, Won Sik
  organization: Idience Co., Ltd
– sequence: 9
  givenname: In-Jin
  orcidid: 0000-0002-8384-3139
  surname: Jang
  fullname: Jang, In-Jin
  organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital
– sequence: 10
  givenname: Kyung-Sang
  orcidid: 0000-0003-0921-7225
  surname: Yu
  fullname: Yu, Kyung-Sang
  email: ksyu@snu.ac.kr
  organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38099989$$D View this record in MEDLINE/PubMed
BookMark eNp9ks9u1DAQxi1URLeFF-CALHHhsAE7zjrxCVWrUhCVqBCcrYkz2XjJ2ovtVGxfhlett1vKnwMnjzW_75ux_J2QI-cdEvKcs9ecsfpN5EyKumClKBiv2KK4eURmfFHnq6zkEZkxLutCKlUfk5MY14wxoerqCTkWDVNKNWpGfp73PZoUqe9p731HwXUU0-CssWlHvaNpQLodIGzA-G_WYbLmjr5GBx1sIdh2ToE6_JGKFToMkGyWXZ19vqLWDba1yYd5LumAMKZhRz_6gODmdAmTgWj35X7qcsjuEekGRqRxatf7vZ6Sxz2MEZ_dn6fk67vzL8v3xeWniw_Ls8vCVKVMRcmRg6mNVDWwtumg6xtlOhCLRaVQ9qzFVpZNJ9qmkqBASVWWsjVM9YwbWYtT8vbgu53aDXYGXQow6m2wGwg77cHqvzvODnrlrzVnjeIlr7LDq3uH4L9PGJPe2GhwHMGhn6IuFStVzZtSZPTlP-jaT8Hl92VKcLYQTMpMvfhzpYddfn1eBsoDYIKPMWD_gHCm9wnRh4TonBB9lxB9k0XiIIoZdisMv2f_R3ULd7_AzQ
Cites_doi 10.1002/bies.20085
10.4161/spmg.24194
10.1007/s00280-017-3512-5
10.1016/j.maturitas.2015.01.015
10.1016/j.eclinm.2019.10.001
10.1158/1535-7163.MCT-22-0068
10.3945/ajcn.2008.27335
10.1038/s41573-020-0076-6
10.1016/j.jsps.2013.02.003
10.1016/j.ygyno.2021.03.015
10.1007/s00280-015-2836-2
10.1007/s11523-021-00796-4
10.3390/nu10080999
10.1139/o05-038
10.1002/cpt.610
10.1038/nrclinonc.2014.163
10.1093/annonc/mdz192
10.1016/S1470-2045(18)30786-1
10.3390/cancers15020448
10.1038/s41568-022-00535-5
10.1038/clpt.2008.141
10.1158/1078-0432.CCR-22-0442
10.1007/s00412-013-0442-9
10.1016/j.autneu.2006.07.011
10.1517/17425255.2012.657626
10.1016/j.chembiol.2021.02.004
10.1016/j.ygyno.2022.01.032
10.1093/jncimonographs/lgi002
10.1007/s40262-022-01167-6
10.1016/j.ejps.2019.04.003
10.1002/cpt.61
10.1111/bcp.15035
10.4162/nrp.2015.9.3.288
10.1186/s40543-023-00373-6
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7QO
7RV
7WY
7WZ
7X7
7XB
87Z
88E
8AO
8FD
8FI
8FJ
8FK
8FL
ABUWG
AFKRA
AZQEC
BENPR
BEZIV
CCPQU
DWQXO
FR3
FRNLG
FYUFA
F~G
GHDGH
K60
K6~
K9-
K9.
KB0
L.-
M0C
M0R
M0S
M1P
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQBIZ
PQBZA
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1007/s10637-023-01405-z
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Nursing & Allied Health Database
ABI/INFORM Collection
ABI/INFORM Global (PDF only)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ABI/INFORM Collection
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ABI/INFORM Collection (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Business Premium Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
Business Premium Collection (Alumni)
Health Research Premium Collection
ABI/INFORM Global (Corporate)
Health Research Premium Collection (Alumni)
ProQuest Business Collection (Alumni Edition)
ProQuest Business Collection
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ABI/INFORM Professional Advanced
ABI/INFORM Global
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Business
ProQuest One Business (Alumni)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ABI/INFORM Global (Corporate)
ProQuest Business Collection (Alumni Edition)
ProQuest One Business
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ABI/INFORM Complete
ProQuest Central
ABI/INFORM Professional Advanced
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ABI/INFORM Complete (Alumni Edition)
Business Premium Collection
ABI/INFORM Global
ABI/INFORM Global (Alumni Edition)
ProQuest Central Basic
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Business Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Business (Alumni)
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
Business Premium Collection (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
ABI/INFORM Global (Corporate)
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-0646
EndPage 88
ExternalDocumentID PMC10891214
38099989
10_1007_s10637_023_01405_z
Genre Journal Article
GrantInformation_xml – fundername: Idience Co., Ltd.
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
1SB
203
28-
29J
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7RV
7WY
7X7
88E
8AO
8FI
8FJ
8FL
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BEZIV
BGNMA
BKEYQ
BKNYI
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
EPAXT
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRNLG
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GROUPED_ABI_INFORM_COMPLETE
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K60
K6~
K9-
KDC
KOV
KOW
KPH
LAK
LLZTM
M0C
M0R
M1P
M4Y
MA-
MK0
N2Q
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQBIZ
PQBZA
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK6
WK8
WOW
YLTOR
Z45
Z7U
Z81
Z82
Z87
Z8O
Z8U
Z8V
Z91
ZGI
ZMTXR
ZOVNA
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
NPM
PJZUB
PPXIY
7QO
7XB
8FD
8FK
FR3
K9.
L.-
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c426t-21e1ac7c697a0b8dadf89cda35549e6f0beb628d3b846a9a969226bc09f01c673
IEDL.DBID U2A
ISSN 0167-6997
1573-0646
IngestDate Thu Aug 21 18:35:15 EDT 2025
Fri Jul 11 08:59:05 EDT 2025
Sat Aug 23 12:33:38 EDT 2025
Mon Jul 21 06:09:04 EDT 2025
Tue Jul 01 03:15:35 EDT 2025
Fri Feb 21 02:40:31 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Ethnic effect
Food effect
Pharmacokinetics
PARP inhibitor
Venadaparib
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c426t-21e1ac7c697a0b8dadf89cda35549e6f0beb628d3b846a9a969226bc09f01c673
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0002-8819-4780
0000-0002-1216-7516
0000-0003-0921-7225
0000-0001-5799-4489
0000-0001-6275-8587
0000-0003-2581-349X
0000-0002-8384-3139
0000-0002-0306-6908
0000-0001-9502-2429
0009-0005-4285-4439
OpenAccessLink https://link.springer.com/10.1007/s10637-023-01405-z
PMID 38099989
PQID 2931053066
PQPubID 37283
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10891214
proquest_miscellaneous_2902971823
proquest_journals_2931053066
pubmed_primary_38099989
crossref_primary_10_1007_s10637_023_01405_z
springer_journals_10_1007_s10637_023_01405_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-02-01
PublicationDateYYYYMMDD 2024-02-01
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationSubtitle Novel Anti-Cancer Therapeutics and Therapies
PublicationTitle Investigational new drugs
PublicationTitleAbbrev Invest New Drugs
PublicationTitleAlternate Invest New Drugs
PublicationYear 2024
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Ramamoorthy, Pacanowski, Bull (CR24) 2015; 97
Wagar, Mojdehbakhsh, Godecker (CR36) 2022; 165
Shetty, Meistrich (CR19) 2005; 34
Curtin, Szabo (CR7) 2020; 19
Lee, Je, Kim (CR10) 2023; 22
Ame, Spenlehauer, De Murcia (CR4) 2004; 26
CR16
CR15
Moore, Zhang, Agarwal (CR27) 2018; 81
Tallis, Morra, Barkauskaite (CR11) 2014; 123
Sonnenblick, De Azambuja, Azim (CR3) 2015; 12
CR33
CR32
CR31
CR30
Maljaars, Romeyn, Haddeman (CR38) 2009; 89
Nicum, Blagden (CR35) 2022; 28
Lafargue, Dal Molin, Sood (CR17) 2019; 20
Jiang, Tao, Liu (CR28) 2022; 88
Konecny, Oza, Tinker (CR29) 2021; 161
Kim, Chen, Yu (CR12) 2021; 28
Mcgraw, Waller (CR34) 2012; 8
Chung, Lee, Lee (CR39) 2015; 9
Malanga, Althaus (CR5) 2005; 83
Mateo, Lord, Serra (CR9) 2019; 30
Koziolek, Alcaro, Augustijns (CR23) 2019; 134
Ovejero-Sanchez, Gonzalez-Sarmiento, Herrero (CR2) 2023; 15
Celik-Ozenci, Tasatargil (CR18) 2013; 3
Groelly, Fawkes, Dagg (CR1) 2023; 23
Cortesi, Rugo, Jackisch (CR8) 2021; 16
Bruin, Sonke, Beijnen (CR25) 2022; 61
Bischoff, Renzer (CR37) 2006; 129
CR22
CR21
Gaal, Kerr, Ward (CR40) 2018; 10
Yasuda, Zhang, Huang (CR14) 2008; 84
CR20
Plummer, Swaisland, Leunen (CR26) 2015; 76
Parsad, Ratain (CR13) 2017; 101
Alomar (CR42) 2014; 22
Tangutoori, Baldwin, Sridhar (CR6) 2015; 81
Watson, Caster, Rochon (CR41) 2019; 17
C Kim (1405_CR12) 2021; 28
K Moore (1405_CR27) 2018; 81
1405_CR15
1405_CR16
M Koziolek (1405_CR23) 2019; 134
JC Ame (1405_CR4) 2004; 26
1405_CR31
SC Bischoff (1405_CR37) 2006; 129
1405_CR32
1405_CR33
R Plummer (1405_CR26) 2015; 76
S Parsad (1405_CR13) 2017; 101
1405_CR30
J Mcgraw (1405_CR34) 2012; 8
C Celik-Ozenci (1405_CR18) 2013; 3
A Sonnenblick (1405_CR3) 2015; 12
S Tangutoori (1405_CR6) 2015; 81
MC Bruin (1405_CR25) 2022; 61
M Ovejero-Sanchez (1405_CR2) 2023; 15
J Maljaars (1405_CR38) 2009; 89
J Mateo (1405_CR9) 2019; 30
M Tallis (1405_CR11) 2014; 123
X Jiang (1405_CR28) 2022; 88
FJ Groelly (1405_CR1) 2023; 23
GE Konecny (1405_CR29) 2021; 161
S Watson (1405_CR41) 2019; 17
M Malanga (1405_CR5) 2005; 83
S Nicum (1405_CR35) 2022; 28
NJ Curtin (1405_CR7) 2020; 19
G Shetty (1405_CR19) 2005; 34
1405_CR20
1405_CR21
1405_CR22
A Ramamoorthy (1405_CR24) 2015; 97
CJ Lafargue (1405_CR17) 2019; 20
S Gaal (1405_CR40) 2018; 10
MJ Alomar (1405_CR42) 2014; 22
M Lee (1405_CR10) 2023; 22
SJ Chung (1405_CR39) 2015; 9
SU Yasuda (1405_CR14) 2008; 84
MK Wagar (1405_CR36) 2022; 165
L Cortesi (1405_CR8) 2021; 16
References_xml – volume: 26
  start-page: 882
  year: 2004
  end-page: 893
  ident: CR4
  article-title: The PARP superfamily
  publication-title: BioEssays
  doi: 10.1002/bies.20085
– volume: 3
  start-page: e24194
  year: 2013
  ident: CR18
  article-title: Role of poly(ADP-ribose) polymerases in male reproduction
  publication-title: Spermatogenesis
  doi: 10.4161/spmg.24194
– ident: CR22
– volume: 81
  start-page: 497
  year: 2018
  end-page: 503
  ident: CR27
  article-title: The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent Ovarian cancer
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-017-3512-5
– volume: 81
  start-page: 5
  year: 2015
  end-page: 9
  ident: CR6
  article-title: PARP inhibitors: a new era of targeted therapy
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2015.01.015
– volume: 17
  start-page: 100188
  year: 2019
  ident: CR41
  article-title: Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2019.10.001
– volume: 22
  start-page: 333
  year: 2023
  end-page: 342
  ident: CR10
  article-title: Venadaparib is a novel and selective PARP inhibitor with Improved Physicochemical Properties, Efficacy, and Safety
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-22-0068
– volume: 89
  start-page: 1019
  year: 2009
  end-page: 1024
  ident: CR38
  article-title: Effect of fat saturation on satiety, hormone release, and food intake
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.2008.27335
– ident: CR16
– volume: 19
  start-page: 711
  year: 2020
  end-page: 736
  ident: CR7
  article-title: Poly(ADP-ribose) polymerase inhibition: past, present and future
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/s41573-020-0076-6
– ident: CR30
– ident: CR33
– volume: 22
  start-page: 83
  year: 2014
  end-page: 94
  ident: CR42
  article-title: Factors affecting the development of adverse drug reactions (review article)
  publication-title: Saudi Pharm J
  doi: 10.1016/j.jsps.2013.02.003
– volume: 161
  start-page: 668
  year: 2021
  end-page: 675
  ident: CR29
  article-title: Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2021.03.015
– volume: 76
  start-page: 723
  year: 2015
  end-page: 729
  ident: CR26
  article-title: Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-015-2836-2
– volume: 16
  start-page: 255
  year: 2021
  end-page: 282
  ident: CR8
  article-title: An overview of PARP inhibitors for the treatment of Breast Cancer
  publication-title: Target Oncol
  doi: 10.1007/s11523-021-00796-4
– volume: 10
  start-page: 999
  year: 2018
  ident: CR40
  article-title: Breakfast consumption in the UK: patterns, nutrient intake and Diet Quality. A study from the International Breakfast Research Initiative Group
  publication-title: Nutrients
  doi: 10.3390/nu10080999
– volume: 83
  start-page: 354
  year: 2005
  end-page: 364
  ident: CR5
  article-title: The role of poly(ADP-ribose) in the DNA damage signaling network
  publication-title: Biochem Cell Biol
  doi: 10.1139/o05-038
– volume: 101
  start-page: 606
  year: 2017
  end-page: 612
  ident: CR13
  article-title: Food Effect studies for Oncology Drug products
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.610
– volume: 12
  start-page: 27
  year: 2015
  end-page: 41
  ident: CR3
  article-title: An update on PARP inhibitors–moving to the adjuvant setting
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2014.163
– volume: 30
  start-page: 1437
  year: 2019
  end-page: 1447
  ident: CR9
  article-title: A decade of clinical development of PARP inhibitors in perspective
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz192
– volume: 20
  start-page: e15
  year: 2019
  end-page: e28
  ident: CR17
  article-title: Exploring and comparing adverse events between PARP inhibitors
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30786-1
– volume: 15
  start-page: 448
  year: 2023
  ident: CR2
  article-title: DNA damage response alterations in Ovarian Cancer: from Molecular mechanisms to Therapeutic opportunities
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers15020448
– ident: CR21
– volume: 23
  start-page: 78
  year: 2023
  end-page: 94
  ident: CR1
  article-title: Targeting DNA damage response pathways in cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-022-00535-5
– volume: 84
  start-page: 417
  year: 2008
  end-page: 423
  ident: CR14
  article-title: The role of ethnicity in variability in response to Drugs: focus on clinical pharmacology studies
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2008.141
– volume: 28
  start-page: 2201
  year: 2022
  end-page: 2203
  ident: CR35
  article-title: PARPs: all for one and one for all? Enhancing diversity in clinical trials
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-22-0442
– ident: CR15
– volume: 123
  start-page: 79
  year: 2014
  end-page: 90
  ident: CR11
  article-title: Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response
  publication-title: Chromosoma
  doi: 10.1007/s00412-013-0442-9
– volume: 129
  start-page: 22
  year: 2006
  end-page: 27
  ident: CR37
  article-title: Nausea and nutrition
  publication-title: Auton Neurosci
  doi: 10.1016/j.autneu.2006.07.011
– ident: CR31
– volume: 8
  start-page: 371
  year: 2012
  end-page: 382
  ident: CR34
  article-title: Cytochrome P450 variations in different ethnic populations
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425255.2012.657626
– volume: 28
  start-page: 456
  year: 2021
  end-page: 462
  ident: CR12
  article-title: Avoid the trap: Targeting PARP1 beyond human malignancy
  publication-title: Cell Chem Biol
  doi: 10.1016/j.chembiol.2021.02.004
– volume: 165
  start-page: 49
  year: 2022
  end-page: 52
  ident: CR36
  article-title: Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2022.01.032
– volume: 34
  start-page: 36
  year: 2005
  end-page: 39
  ident: CR19
  article-title: Hormonal approaches to preservation and restoration of male fertility after cancer treatment
  publication-title: J Natl Cancer Inst Monogr
  doi: 10.1093/jncimonographs/lgi002
– volume: 61
  start-page: 1649
  year: 2022
  end-page: 1675
  ident: CR25
  article-title: Pharmacokinetics and pharmacodynamics of PARP inhibitors in Oncology
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-022-01167-6
– ident: CR32
– volume: 134
  start-page: 31
  year: 2019
  end-page: 59
  ident: CR23
  article-title: The mechanisms of pharmacokinetic food-drug interactions - a perspective from the UNGAP group
  publication-title: Eur J Pharm Sci
  doi: 10.1016/j.ejps.2019.04.003
– volume: 97
  start-page: 263
  year: 2015
  end-page: 273
  ident: CR24
  article-title: Racial/ethnic differences in drug disposition and response: review of recently approved Drugs
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.61
– volume: 88
  start-page: 1087
  year: 2022
  end-page: 1093
  ident: CR28
  article-title: A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.15035
– volume: 9
  start-page: 288
  year: 2015
  end-page: 295
  ident: CR39
  article-title: Breakfast skipping and breakfast type are associated with daily nutrient intakes and metabolic syndrome in Korean adults
  publication-title: Nutr Res Pract
  doi: 10.4162/nrp.2015.9.3.288
– ident: CR20
– volume: 101
  start-page: 606
  year: 2017
  ident: 1405_CR13
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.610
– volume: 19
  start-page: 711
  year: 2020
  ident: 1405_CR7
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/s41573-020-0076-6
– volume: 22
  start-page: 333
  year: 2023
  ident: 1405_CR10
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-22-0068
– volume: 76
  start-page: 723
  year: 2015
  ident: 1405_CR26
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-015-2836-2
– volume: 8
  start-page: 371
  year: 2012
  ident: 1405_CR34
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425255.2012.657626
– ident: 1405_CR22
– volume: 165
  start-page: 49
  year: 2022
  ident: 1405_CR36
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2022.01.032
– ident: 1405_CR21
  doi: 10.1186/s40543-023-00373-6
– volume: 123
  start-page: 79
  year: 2014
  ident: 1405_CR11
  publication-title: Chromosoma
  doi: 10.1007/s00412-013-0442-9
– volume: 34
  start-page: 36
  year: 2005
  ident: 1405_CR19
  publication-title: J Natl Cancer Inst Monogr
  doi: 10.1093/jncimonographs/lgi002
– ident: 1405_CR15
– volume: 22
  start-page: 83
  year: 2014
  ident: 1405_CR42
  publication-title: Saudi Pharm J
  doi: 10.1016/j.jsps.2013.02.003
– volume: 84
  start-page: 417
  year: 2008
  ident: 1405_CR14
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2008.141
– volume: 28
  start-page: 456
  year: 2021
  ident: 1405_CR12
  publication-title: Cell Chem Biol
  doi: 10.1016/j.chembiol.2021.02.004
– ident: 1405_CR32
– volume: 83
  start-page: 354
  year: 2005
  ident: 1405_CR5
  publication-title: Biochem Cell Biol
  doi: 10.1139/o05-038
– ident: 1405_CR30
– volume: 28
  start-page: 2201
  year: 2022
  ident: 1405_CR35
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-22-0442
– volume: 10
  start-page: 999
  year: 2018
  ident: 1405_CR40
  publication-title: Nutrients
  doi: 10.3390/nu10080999
– volume: 15
  start-page: 448
  year: 2023
  ident: 1405_CR2
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers15020448
– ident: 1405_CR33
– volume: 89
  start-page: 1019
  year: 2009
  ident: 1405_CR38
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.2008.27335
– volume: 9
  start-page: 288
  year: 2015
  ident: 1405_CR39
  publication-title: Nutr Res Pract
  doi: 10.4162/nrp.2015.9.3.288
– volume: 30
  start-page: 1437
  year: 2019
  ident: 1405_CR9
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz192
– volume: 12
  start-page: 27
  year: 2015
  ident: 1405_CR3
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2014.163
– volume: 16
  start-page: 255
  year: 2021
  ident: 1405_CR8
  publication-title: Target Oncol
  doi: 10.1007/s11523-021-00796-4
– volume: 97
  start-page: 263
  year: 2015
  ident: 1405_CR24
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.61
– volume: 88
  start-page: 1087
  year: 2022
  ident: 1405_CR28
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.15035
– volume: 20
  start-page: e15
  year: 2019
  ident: 1405_CR17
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30786-1
– ident: 1405_CR20
– volume: 81
  start-page: 497
  year: 2018
  ident: 1405_CR27
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-017-3512-5
– volume: 161
  start-page: 668
  year: 2021
  ident: 1405_CR29
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2021.03.015
– volume: 129
  start-page: 22
  year: 2006
  ident: 1405_CR37
  publication-title: Auton Neurosci
  doi: 10.1016/j.autneu.2006.07.011
– volume: 61
  start-page: 1649
  year: 2022
  ident: 1405_CR25
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-022-01167-6
– volume: 23
  start-page: 78
  year: 2023
  ident: 1405_CR1
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-022-00535-5
– volume: 3
  start-page: e24194
  year: 2013
  ident: 1405_CR18
  publication-title: Spermatogenesis
  doi: 10.4161/spmg.24194
– volume: 17
  start-page: 100188
  year: 2019
  ident: 1405_CR41
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2019.10.001
– volume: 134
  start-page: 31
  year: 2019
  ident: 1405_CR23
  publication-title: Eur J Pharm Sci
  doi: 10.1016/j.ejps.2019.04.003
– volume: 26
  start-page: 882
  year: 2004
  ident: 1405_CR4
  publication-title: BioEssays
  doi: 10.1002/bies.20085
– volume: 81
  start-page: 5
  year: 2015
  ident: 1405_CR6
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2015.01.015
– ident: 1405_CR16
– ident: 1405_CR31
SSID ssj0003974
Score 2.3812542
Snippet Aim Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the...
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects...
AimVenadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 80
SubjectTerms Dosage
Ethnicity
Food
Gastric cancer
Inhibitors
Labels
Males
Medicine
Medicine & Public Health
Minority & ethnic groups
Oncology
Oral administration
Pharmacokinetics
Pharmacology/Toxicology
Poly(ADP-ribose)
Poly(ADP-ribose) polymerase
Ribose
Statistical analysis
Targeted cancer therapy
Time measurement
White people
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgien5VTxlB7sUG2203H09yHB6HoixyB_tWkiZxl8N0ve4-7P0z_qvOtN1d1kPfAkmThplkfslMfsPYu7GzdWF1wRG7Ol4KE7jJ64zrzMjSWh1C6AJkv4nzy_LzdDwdLtzaIaxysyd2G7Vraroj_4BmCaEAAlzxcfGLU9Yo8q4OKTTusntEXUYhXXK6PXBlaGu33N5Cazk8mhmezolCcrRYnM4YY36zb5huoc3bQZN_eU47g3T2iD0ckCSc9KJ_zO74eMjufx185YfseNKzUq9TuNg9smpTOIbJjq96_YT97hmMW2gChKZxYKIDv5xF7Gi5hiYCgkRYDN9cYefUD7XGjdI4Q3kMbQoGIp2if3Q81iRumJx8n8A8zuYWt43rFIvQP7tcw5cGwWpM4dRQ0rU5FWlUyubtWw8_0WxBu7J0SdQ-ZZdnny5Oz_mQt4HXaO-XfJT73NSyFlqazCpnXFC6doagjfYiZNZbMVKusAh-jDZaaASBts50yPJayOIZO4hN9C8Y5KFQMmSF9UKVY6PVWDrKUCNdKaWqdcLeb4RWLXp6jmpHxEwirlDEVSfi6iZhRxu5VsNSbaudYiXs7bYaFxl5Tkz0zYraUI4vVOciYc97NdgOVygC2Qp_Re0pyLYBEXjv18T5rCPyzjOl81FeJizd6NLuv_49jZf_n8Yr9mCEyKsPLT9iB8vrlX-NyGlp33TL4w_fdxf5
  priority: 102
  providerName: ProQuest
Title Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
URI https://link.springer.com/article/10.1007/s10637-023-01405-z
https://www.ncbi.nlm.nih.gov/pubmed/38099989
https://www.proquest.com/docview/2931053066
https://www.proquest.com/docview/2902971823
https://pubmed.ncbi.nlm.nih.gov/PMC10891214
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfYJiFeEIyvwqiMhPZCIiVN4o_HtmqZmKiqaZXKU2TH9lohnGlpH7p_hn-VuyRtKYMHnmzJjuPozr7fxb7fEfIxM7pItExCwK4mTJlyoYqLKJSR4qnW0jlXX5CdsItZ-mWezdugsGp72317JFnv1L8Fu7GEh2BjQvQKsvD-iJxk6LuDFs96_d3-CxZ2x-jNpORtqMzfxzg0Rw8w5sOrkn-cl9ZmaPyMPG3xI-03An9OHll_Sh5_bU_IT8n5tOGi3gT0eh9aVQX0nE73LNWbF-Rnw1tc0dJRV5aGKm-oXS08DLTa0NJTgIb0tn3mOwyO42Bv2B6VUZi9UAdUUY--803NXo1CptP-1ZQu_WKpYbO4C6BKm2DLDb0sAaL6gA4VplpbYhXfijm8bWXpDzBWtFpr_DVUvSSz8eh6eBG22RrCAqz8KuzFNlYFL5jkKtLCKOOELIxCQCMtc5G2mvWESTRAHiWVZBKgny4i6aK4YDx5RY596e0bQmOXCO6iRFsm0kxJkXGDeWm4STkXheyQT1uh5bcNKUe-p19GEecg4rwWcX7fIWdbuebtAq1yQDmALMFfYh3yYdcMSwvPS5S35Rr7YGYvUOKkQ143arB7XSIQWguYijhQkF0HpO0-bPHLRU3fHUdCxr047ZBgq0v7ef37M97-X_d35AmsjbS5YH5Gjld3a_se8NNKd8kRn_MuOemPB4MJlp-_XY6gHIwm0ytoHbJht15SvwDmpRvW
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VVAJeEJRboMAgQV-whW-xdx8QKqVVS9ooqlKpb-6ud00ixDrUiVD6M_wB38iML4lCBW99s-T12tbMzjl7mTOMvelplYVKhC5yV-1Gscxd6WeeKzyZREqJPM-rA7KD-PAs-nLeO99gv9tcGDpW2cbEKlDrIqM18vcIS0gFkODGH6c_XKoaRburbQmN2i36ZvETp2zlh6PPaN-3QXCwP9o7dJuqAm6GaDRzA9_4MkuyWCTSU1xLnXORaUnAK0yce8qoOOA6VAjNUkgRC6QoKvNE7vlZnITY7y22GYU4lemwzU_7g-HpMvYjui_VxGMhkiZNp0nWi8PERYx0aVbTc6_WofAav71-TPOvvdoKAg_us3sNd4Xd2tkesA1jt9jtk2Z3fovtDGsd7IUDo1VaV-nADgxXCtmLh-xXrZlcQpFDXhQapNVgZmOLHc0WUFhAWgrT5plv2Dn1Q60xNEstqXKickCCpXn710o5mxwMhrunQ5jY8URhoLp08BLqRM8F9Aukx9aBPUll3iZ0SW-l-uGmNPAdgRLKuaJlqfIRO7sRmz5mHVtY85SBn4c8yb1QmZhHPSl4L9FUEyfRUZLwTHTZu9Zo6bQWBElX0s9k4hRNnFYmTq-6bLu1a9oEhzJduXKXvV7exmFNezXSmmJObaiqGA6gsMue1G6wfF3IidZz_BS-5iDLBiQZvn7HTsaVdLjvceEHftRlTutLq-_69288-_9vvGJ3Dkcnx-nx0aD_nN0NkPfVB9u3WWd2OTcvkLfN1MtmsAC7uOnx-QdJmlbW
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkCZeEIzLCgOMBHsh0XK3_YDQtFFtFKYKbVLfgh3btJrmlKUV6v4M_4Nfxzm5tCoTvO0tUhwn0bl8n-1zIeRNqlURKxH7wF21n2TS-jIsAl8EkiVKCWttHSB7mh2fJ59G6WiD_O5yYTCssvOJtaPWZYF75PsAS0AFgOBm-7YNixge9T9Mf_jYQQpPWrt2Go2KDMziJyzfqvcnRyDrt1HU_3h2eOy3HQb8ApBp5kehCWXBikwwGSiupbZcFFoiCAuT2UAZlUVcxwpgWgopMgF0RRWBsEFYZCyGee-QuyxOQ7QxNlou9gLA-WVd8UwI1ibstGl7Wcx8QEsf1zepf70OijeY7s2Azb9ObWsw7D8g91sWSw8atXtINozbJltf2nP6bbI3bCpiLzx6tkrwqjy6R4erWtmLR-RXUz25oqWltiw1lU5TMxs7mGi2oKWjQFDptH3mAibHeXA0OGmpJfZQVB6V1OEK_ntdQxtVjQ4Pvg7pxI0nClzWlQeXtEn5XNBBCUTZefRQYsO3CV7iW7GTuKkMvQTIpNVc4QZV9Zic34pEn5BNVzqzQ2hoY85sECuT8SSVgqdMY3ccphPGeCF65F0ntHzalAbJV0WgUcQ5iDivRZxf98huJ9e8dRNVvlLqHnm9vA0Gjqc20plyjmOwvxiYUtwjTxs1WL4u5kjwOXwKX1OQ5QAsHr5-x03GdRHxMOAijMKkR7xOl1bf9e_fePb_33hFtsAq888np4Pn5F4EBLCJcN8lm7OruXkBBG6mXtaWQsm32zbNP2IVWaY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+food+and+ethnicity+on+the+pharmacokinetics+of+venadaparib%2C+a+next-generation+PARP+inhibitor%2C+in+healthy+Korean%2C+Caucasian%2C+and+Chinese+male+subjects&rft.jtitle=Investigational+new+drugs&rft.au=Kim%2C+Hyun+Chul&rft.au=Yang%2C+Eunsol&rft.au=Lee%2C+Soyoung&rft.au=Oh%2C+Jaeseong&rft.date=2024-02-01&rft.pub=Springer+US&rft.issn=0167-6997&rft.eissn=1573-0646&rft.volume=42&rft.issue=1&rft.spage=80&rft.epage=88&rft_id=info:doi/10.1007%2Fs10637-023-01405-z&rft.externalDocID=10_1007_s10637_023_01405_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6997&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6997&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6997&client=summon